Adlai Nortye Biopharma
Xuyang Song, PhD, MBA has worked in a variety of roles in the pharmaceutical industry since 2007. In 2007, they began as a Research Scientist at the University of Florida. In 2012, they became a Summer Intern at Pfizer and a The Oak Ridge Institute for Science and Education (ORISE) Research Fellow at the FDA. In 2013, they were a Summer Student at Uppsala University. From 2014-2022, they held various roles at AstraZeneca, including Director, Clinical and Quantitative Pharmacology, Associate Director (Principal Scientist), Senior Clinical Pharmacokineticist (Associate Principal Scientist), and Clinical Pharmacokineticist. In 2022, they became the Executive Director, Global Head of Clinical Pharmacology at Adlai Nortye Biopharma Co., Ltd.
Xuyang Song, PhD, MBA obtained their Bachelor of Science degree from Shenyang Pharmaceutical University in the College of Business Administration, Pharmaceutics and International Trade. Xuyang then went on to complete a Master of Science degree in Biostatistics from the University of Florida. Following this, they completed a Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences from the University of Florida. Lastly, they completed a Master of Business Administration - MBA (executive) from the University of Cambridge's Queens College.
This person is not in any offices
Adlai Nortye Biopharma
1 followers
Adlai Nortye Biopharma is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, they have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. They have assembled a world-class management team, built a unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation.